Cargando…

Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia

OBJECTIVE: An important challenge in schizophrenia therapeutics is to develop an efficacious treatment for cognitive impairment. Acetylcholinesterase inhibitors, such as rivastigmine, have been studied for improving cognitive performance in these patients. MATERIALS AND METHODS: Rivastigmine (uptitr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Pattath Narayanan Suresh, Mohemmedali, Seema P., Anish, P. K., Andrade, Chittaranjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547865/
https://www.ncbi.nlm.nih.gov/pubmed/28827871
http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_133_16
_version_ 1783255750153338880
author Kumar, Pattath Narayanan Suresh
Mohemmedali, Seema P.
Anish, P. K.
Andrade, Chittaranjan
author_facet Kumar, Pattath Narayanan Suresh
Mohemmedali, Seema P.
Anish, P. K.
Andrade, Chittaranjan
author_sort Kumar, Pattath Narayanan Suresh
collection PubMed
description OBJECTIVE: An important challenge in schizophrenia therapeutics is to develop an efficacious treatment for cognitive impairment. Acetylcholinesterase inhibitors, such as rivastigmine, have been studied for improving cognitive performance in these patients. MATERIALS AND METHODS: Rivastigmine (uptitrated to 6 mg/day) was given as an add-on therapy to risperidone-treated stable schizophrenia patients in a randomized, double-blind, placebo-controlled design. Of 67 patients who met eligibility criteria, 55 were recruited into the study. Twenty-eight were assigned to rivastigmine and 27 to placebo. These patients completed tests of attention, executive functioning, verbal skills, verbal and visuospatial working memory, and psychomotor speed on five occasions: at baseline, and at the end of the 1(st), 3(rd), 6(th), and 12(th) months. RESULTS: The groups were similar in terms of sociodemographic profile and baseline clinical characteristics (Positive and Negative Syndrome Scale and Clinical Global Impression-Severity). Contrary to expectations, rivastigmine patients showed poorer outcomes on several cognitive measures. Rivastigmine patients experienced also more psychological as well as neurological side effects. Core psychopathology ratings, however, did not differ between rivastigmine and placebo groups. CONCLUSIONS: Our study does not support the long-term use of rivastigmine as an augmentation agent in schizophrenia. Rivastigmine may be associated with higher incidence of psychological and neurological side effects in patients with schizophrenia.
format Online
Article
Text
id pubmed-5547865
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-55478652017-08-21 Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia Kumar, Pattath Narayanan Suresh Mohemmedali, Seema P. Anish, P. K. Andrade, Chittaranjan Indian J Psychiatry Original Article OBJECTIVE: An important challenge in schizophrenia therapeutics is to develop an efficacious treatment for cognitive impairment. Acetylcholinesterase inhibitors, such as rivastigmine, have been studied for improving cognitive performance in these patients. MATERIALS AND METHODS: Rivastigmine (uptitrated to 6 mg/day) was given as an add-on therapy to risperidone-treated stable schizophrenia patients in a randomized, double-blind, placebo-controlled design. Of 67 patients who met eligibility criteria, 55 were recruited into the study. Twenty-eight were assigned to rivastigmine and 27 to placebo. These patients completed tests of attention, executive functioning, verbal skills, verbal and visuospatial working memory, and psychomotor speed on five occasions: at baseline, and at the end of the 1(st), 3(rd), 6(th), and 12(th) months. RESULTS: The groups were similar in terms of sociodemographic profile and baseline clinical characteristics (Positive and Negative Syndrome Scale and Clinical Global Impression-Severity). Contrary to expectations, rivastigmine patients showed poorer outcomes on several cognitive measures. Rivastigmine patients experienced also more psychological as well as neurological side effects. Core psychopathology ratings, however, did not differ between rivastigmine and placebo groups. CONCLUSIONS: Our study does not support the long-term use of rivastigmine as an augmentation agent in schizophrenia. Rivastigmine may be associated with higher incidence of psychological and neurological side effects in patients with schizophrenia. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5547865/ /pubmed/28827871 http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_133_16 Text en Copyright: © 2017 Indian Journal of Psychiatry http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kumar, Pattath Narayanan Suresh
Mohemmedali, Seema P.
Anish, P. K.
Andrade, Chittaranjan
Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
title Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
title_full Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
title_fullStr Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
title_full_unstemmed Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
title_short Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
title_sort cognitive effects with rivastigmine augmentation of risperidone: a 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547865/
https://www.ncbi.nlm.nih.gov/pubmed/28827871
http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_133_16
work_keys_str_mv AT kumarpattathnarayanansuresh cognitiveeffectswithrivastigmineaugmentationofrisperidonea12monthrandomizeddoubleblindplacebocontrolledstudyinschizophrenia
AT mohemmedaliseemap cognitiveeffectswithrivastigmineaugmentationofrisperidonea12monthrandomizeddoubleblindplacebocontrolledstudyinschizophrenia
AT anishpk cognitiveeffectswithrivastigmineaugmentationofrisperidonea12monthrandomizeddoubleblindplacebocontrolledstudyinschizophrenia
AT andradechittaranjan cognitiveeffectswithrivastigmineaugmentationofrisperidonea12monthrandomizeddoubleblindplacebocontrolledstudyinschizophrenia